Predictive Oncology Becomes Axe Compute Expanding Into High Axe compute will continue to operate its ai driven drug discovery business and plans to expand its business into high performance enterprise ai infrastructure, addressing rising global. Predictive oncology (nasdaq: poai) announced that it has changed its name to axe compute inc., with its common stock to begin trading on nasdaq under the ticker symbol agpu on december 12, 2025.
Predictive Oncology Becomes Axe Compute Expanding Into Axe compute will continue to operate its ai driven drug discovery business and plans to expand its business into high performance enterprise ai infrastructure, addressing rising global demand for predictable, scalable compute capacity across enterprise ai workloads. Axe compute will continue to operate its ai driven drug discovery business and plans to expand its business into high performance enterprise ai infrastructure, addressing rising global. Axe compute will continue to operate its ai driven drug discovery business and plans to expand its business into high performance enterprise ai infrastructure, addressing rising global demand for predictable, scalable compute capacity across enterprise ai workloads. Axe compute adopts new name and expands from ai drug discovery into high performance enterprise ai infrastructure, targeting gpu gaps as waits hit 40 52 weeks.
Predictive Oncology Becomes Axe Compute Expanding Into Axe compute will continue to operate its ai driven drug discovery business and plans to expand its business into high performance enterprise ai infrastructure, addressing rising global demand for predictable, scalable compute capacity across enterprise ai workloads. Axe compute adopts new name and expands from ai drug discovery into high performance enterprise ai infrastructure, targeting gpu gaps as waits hit 40 52 weeks.
Predictive Oncology Becomes Axe Compute With High Performance Ai
Comments are closed.